{"id":70,"date":"2007-04-04T23:55:00","date_gmt":"2007-04-04T15:55:00","guid":{"rendered":"https:\/\/flcube.com\/?p=70"},"modified":"2024-11-23T22:33:43","modified_gmt":"2024-11-23T14:33:43","slug":"china-biopharma-posts-216-revenue-increase-eyes-us10-million-in-2007-with-vaccine-distribution-and-new-treatments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70","title":{"rendered":"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments"},"content":{"rendered":"\n<p>China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a remarkable leap in its financial results for 2006 on April 2nd. The company reported a staggering 216% increase in total revenues, surging from US$380,519 in 2005 to US$1.2 million in 2006. This revenue growth was predominantly driven by the company&#8217;s vaccine distribution business, marking a strategic shift from value-added communication services in the U.S. to the burgeoning Chinese biopharmaceutical sector.<\/p>\n\n\n\n<p>Chairman and CEO Peter Wang is projecting an ambitious target for 2007, with revenues estimated to hit US$10 million. This projection is underpinned by the company&#8217;s plans to supply preventive vaccines to the Chinese Center for Disease Control and Prevention and to launch its inaugural IVIG treatment for autoimmune diseases. Furthermore, China Biopharma intends to capitalize on its majority-owned subsidiary, Hainan CITIC Bio-Pharmaceutical Development Co., utilizing its distribution platform to expand the delivery of a range of medical products.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[525],"class_list":["post-70","post","type-post","status-publish","format-standard","hentry","category-company","tag-china-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a remarkable leap in its financial results for 2006 on April 2nd. The company reported a staggering 216% increase in total revenues, surging from US$380,519 in 2005 to US$1.2 million in 2006. This revenue growth was predominantly driven by the company&#039;s vaccine distribution business, marking a strategic shift from value-added communication services in the U.S. to the burgeoning Chinese biopharmaceutical sector.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2007-04-04T15:55:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-23T14:33:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments\",\"datePublished\":\"2007-04-04T15:55:00+00:00\",\"dateModified\":\"2024-11-23T14:33:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70\"},\"wordCount\":172,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Biopharma\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70#respond\"]}],\"copyrightYear\":\"2007\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70\",\"name\":\"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2007-04-04T15:55:00+00:00\",\"dateModified\":\"2024-11-23T14:33:43+00:00\",\"description\":\"China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a remarkable leap in its financial results for 2006 on April 2nd. The company reported a staggering 216% increase in total revenues, surging from US$380,519 in 2005 to US$1.2 million in 2006. This revenue growth was predominantly driven by the company's vaccine distribution business, marking a strategic shift from value-added communication services in the U.S. to the burgeoning Chinese biopharmaceutical sector.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments - Insight, China&#039;s Pharmaceutical Industry","description":"China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a remarkable leap in its financial results for 2006 on April 2nd. The company reported a staggering 216% increase in total revenues, surging from US$380,519 in 2005 to US$1.2 million in 2006. This revenue growth was predominantly driven by the company's vaccine distribution business, marking a strategic shift from value-added communication services in the U.S. to the burgeoning Chinese biopharmaceutical sector.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70","og_locale":"en_US","og_type":"article","og_title":"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=70","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2007-04-04T15:55:00+00:00","article_modified_time":"2024-11-23T14:33:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments","datePublished":"2007-04-04T15:55:00+00:00","dateModified":"2024-11-23T14:33:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70"},"wordCount":172,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Biopharma"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70#respond"]}],"copyrightYear":"2007","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70","url":"https:\/\/flcube.com\/?p=70","name":"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2007-04-04T15:55:00+00:00","dateModified":"2024-11-23T14:33:43+00:00","description":"China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a remarkable leap in its financial results for 2006 on April 2nd. The company reported a staggering 216% increase in total revenues, surging from US$380,519 in 2005 to US$1.2 million in 2006. This revenue growth was predominantly driven by the company's vaccine distribution business, marking a strategic shift from value-added communication services in the U.S. to the burgeoning Chinese biopharmaceutical sector.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70\/revisions"}],"predecessor-version":[{"id":14535,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70\/revisions\/14535"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}